---
title: 'Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia
  (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of
  the Bosutinib Dose Optimization (BODO) Study'
date: '2023-08-17'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37592092/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20230818180932&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: The approved dose of bosutinib in chronic phase CML is 400 mg QD in first-line
  and 500 mg QD in later-line treatment. However, given that gastrointestinal (GI)
  toxicity typically occurs early after treatment initiation, physicians often tend
  to start therapy with lower doses although this has never been tested systematically
  in prospective trials in the Western world. The Bosutinib Dose Optimization (BODO)
  Study, a multicenter phase II study, investigated the tolerability and efficacy
  of ...
disable_comments: true
---
The approved dose of bosutinib in chronic phase CML is 400 mg QD in first-line and 500 mg QD in later-line treatment. However, given that gastrointestinal (GI) toxicity typically occurs early after treatment initiation, physicians often tend to start therapy with lower doses although this has never been tested systematically in prospective trials in the Western world. The Bosutinib Dose Optimization (BODO) Study, a multicenter phase II study, investigated the tolerability and efficacy of ...